Key facts
- A.D.A.M. Innovations’s last known valuation is $388.7M (Feb 2018).
- It has raised $47.4M across 5 recorded rounds; the latest was Later Stage VC in Mar 2026.
- Notable investors include Mitsui & Co, Rakuten Capital, Crewstone International, Tokyo Founders Fund, Ci:z Investment — 6 tracked in total.
- Status: Privately Held (backing).
Leadership
- Michel MommejatPresident, Chief Innovation Officer, General Member & Board Member
- Takeru MiyaharaChief Technology Officer
- Shuichi TaniguchiChief Commercial Officer
- David BaranCo-Founder & Chairman
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for A.D.A.M. Innovations
Funding rounds
5 roundsAbout A.D.A.M. Innovations
Provider of genetic research and testing services intended to offer clinically validated genetic testing. The company's services include consumer-based testing, diagnostic testing, and gene therapy, using polymerase chain reaction, microarray, or sequencing technologies, and also provides a range of at-home DNA test kits, enabling patients to achieve health and wellness goals.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2004
- Employees
- 50
- Website
- adam-innovations.com/
- Ownership
- Privately Held (backing)
A.D.A.M. Innovations doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in A.D.A.M. Innovations shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on A.D.A.M. Innovations in its N-PORT filings yet. We sweep new filings monthly.